Home › Funds › Bain Capital Life Sciences Investors, LLC › ALKS
Bain Capital Life Sciences Investors, LLC position in ALKS
ALKERMES PLC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 1,937,938 shares of ALKS (ALKERMES PLC) in its Q2 2026 13F filing — a position valued at US$101.5M, representing 6.04% of its reported portfolio and ranking #5 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed ALKS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's ALKS position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in ALKS in Q1 2026 at 610,000 shares (US$21.6M). The position peaked in Q2 2026 at 1,937,938 shares, worth US$101.5M. Across 2 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,937,938 shares valued at US$101.5M — an increase of 1,327,938 shares quarter over quarter.. Notable position changes include a 218% increase in Q2 2026 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 610.00K | $21.57M | New |
| Q2 2026 | 1.94M | $101.54M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALKS and 13F data
ALKS (ALKERMES PLC) is a Health Care company. 42 other funds we track also report a position in ALKS — the largest reported positions include BAKER BROS. ADVISORS LP (US$524.6M), Renaissance Technologies (US$338.5M), Deep Track Capital, LP (US$209.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALKS
- BAKER BROS. ADVISORS LP 10.01M sh · $524.59M · Q2 2026
- Renaissance Technologies 6.46M sh · $338.52M · Q2 2026
- Deep Track Capital, LP 4.00M sh · $209.58M · Q2 2026
- Commodore Capital LP 3.00M sh · $157.19M · Q2 2026
- BVF INC/IL 2.15M sh · $112.90M · Q2 2026
- RTW INVESTMENTS, LP 1.67M sh · $87.62M · Q2 2026
- Soleus Capital Management, L.P. 1.03M sh · $53.93M · Q2 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held ALKS?
Bain Capital Life Sciences Investors, LLC has disclosed ALKS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Bain Capital Life Sciences Investors, LLC's current position in ALKS?
As of Q2 2026, Bain Capital Life Sciences Investors, LLC holds 1.94M shares of ALKS (ALKERMES PLC), valued at $101.54M, representing 6.04% of its reported portfolio and ranking #5.
Has Bain Capital Life Sciences Investors, LLC been buying or selling ALKS?
In the latest 13F filing (Q2 2026), Bain Capital Life Sciences Investors, LLC increased its position in ALKS. The position peaked in Q2 2026 at 1.94M shares.
Which other funds hold ALKS?
Other major institutional holders of ALKS include BAKER BROS. ADVISORS LP, Renaissance Technologies, Deep Track Capital, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.